SB 927 Oklahoma Senate · 2026 Regular Session

State Medicaid program; modifying appointment procedures for the Medicaid Drug Utilization Review Board. Effective date.

SB 927 amends Oklahoma's Medicaid Drug Utilization Review Board procedures by prohibiting the pharmaceutical industry representative from voting on drug-related matters. It updates the appointment process to stagger initial terms for one physician, one pharmacist, and the lay representative to ensure board continuity. The bill affects the Oklahoma Health Care Authority and the board members, with changes taking effect November 1, 2025. The board's composition (10 members: 4 physicians, 4 pharmacists, 1 lay representative, 1 pharmaceutical industry rep) and appointment lists remain unchanged.
Bill status vetoed 4 of 5 stages cleared
Introduction
Feb 2025
Committee Review
May 2025
Senate Passage
Mar 2025
House Passage
May 2025
Vetoed
May 2025
Introduced Feb 3, 2025 Vetoed May 14, 2025
Maddy AI version diff · 4 comparisons

What changed between versions

Floor (House) Floor (Senate) · 6 edits
MODERATE
The bill was moved from the House version to the Senate floor version, with substantive changes to the composition and appointment rules for the Medicaid Drug Utilization Review Board. The Senate version adds specific requirements for industry representation and voting restrictions, while also clarifying term lengths and staggered appointment procedures.
Scope change
The bill's scope remains focused on the Medicaid Drug Utilization Review Board, but the Senate version introduces more detailed requirements for board member selection and voting restrictions for industry representatives.
REQUIREMENT

Added specific voting restrictions for the pharmaceutical industry representative who cannot vote on drug-related items

Changed physician appointment requirements to specify three physicians from OSMAS and one from OOA

Clarified that the lay community representative must be a healthcare professional with specific expertise in drug use review or quality assurance

Added requirement for pharmaceutical industry representative from Pharmaceutical Research and Manufacturers of America

Added geographic balance requirement when making appointments to the board

TIMELINE

Changed effective date from unspecified to November 1, 2025

Floor votes · Senate Mar 17, 2025 · House May 7, 2025

How they voted

460
Passed · 3 other
Total votes 49
Mar 17, 2025
D Democratic9
9 Yea
100% Yea
R Republican40
37 Yea 3
92% Yea
Vote distribution
All Yea All Nay Mixed No data
Full legislative history

Actions timeline

Total actions
24
Key actions
6
Committee
6
May 14, 2025
Vetoed
Vetoed 05/14/2025
upper
May 7, 2025
Committee
Referred for enrollment
upper
May 7, 2025
Lower · Passed
Third Reading, Measure passed: Ayes: 56 Nays: 31
lower
Apr 16, 2025
Lower · Passed
CR; Do Pass Health and Human Services Oversight Committee
lower
Apr 9, 2025
Lower · Passed
Policy recommendation to the Health and Human Services Oversight committee; Do Pass Public Health
lower
Apr 1, 2025
Committee
Referred to Public Health
lower
Mar 18, 2025
Introduced
First Reading
lower
Mar 18, 2025
Upper · Passed
Engrossed to House
upper
Mar 17, 2025
Committee
Referred for engrossment
upper
Mar 17, 2025
Upper · Passed
Measure passed: Ayes: 44 Nays: 0
upper
Feb 24, 2025
Upper · Passed
Reported Do Pass Health and Human Services committee; CR filed
upper
Feb 3, 2025
Introduced
First Reading
upper
2 primary · 0 co-sponsors

Sponsors